Diagnostic Performance of Myocardial Innervation Imaging Using MIBG Scintigraphy in Differential Diagnosis between Dementia with Lewy Bodies and Other Dementias: A Systematic Review and a Meta-Analysis

Journal of Neuroimaging

Volumn 22, Issue 2, 2012, Pages 111-117

  Treglia, Giorgio ^a   Cason, Ernesto ^b   Giordano, Alessandro ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b MAGGIORE HOSPITAL   (Italy)

Author keywords

Dementia; Dementia with lewy bodies; Metaiodobenzylguanidine; MIBG

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123;

DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; LEWY BODY; META ANALYSIS; MYOCARDIAL PERFUSION IMAGING; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

BRAIN; DEMENTIA; DIAGNOSIS, DIFFERENTIAL; HEART; HUMANS; LEWY BODY DISEASE; MYOCARDIAL PERFUSION IMAGING;

EID: 84859724899     PISSN: 10512284     EISSN: 15526569     Source Type: Journal    
DOI: 10.1111/j.1552-6569.2010.00532.x     Document Type: Review

References (46)

1. Tateno M, Kobayashi S, Saito T. Imaging improves diagnosis of dementia with Lewy bodies. Psychiatry Invest 2009;6:233-240.
2. McKeith I, Mintzer J, Aarsland D, et al. International Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies. Lancet Neurology 2004;3:19-28.
3. McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 2005;65:1863-1872.
4. Weisman D, McKeith I. Dementia with Lewy bodies. Semin Neurol 2007;27:42-47.
5. Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 2007;34:939-950.
6. Nakajima K, Yoshita M, Matsuo S, et al. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging 2008;52:378-387.
7. Treglia G, Cason E, Gabellini A, et al. Recent developments in innervation imaging using iodine-123-metaiodobenzylguanidine scintigraphy in Lewy body diseases. Neurol Sci 2010;31:417-422.
8. Rascol O, Schelosky L. 123I-metaiodobenzylguanidine scintigraphy in Parkinson's disease and related disorders. Mov Disord 2009;24(Suppl 2):S732-S741.
9. Hishikawa N, Hashizume Y, Yoshida M, et al. Clinical and neuropathological correlates of Lewy body disease. Acta Neuropathol (Berl) 2003;105:341-350.
10. Aarsland D, Kurz M, Bronnick K, et al. Early discriminatory diagnosis of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2008;25:195-205.
11. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31.
12. Fröhlich I, Pilloy W, Vaillant M, et al. Myocardial MIBG scintigraphy: a useful clinical tool?: a retrospective study in 50 parkinsonian patients. Neurol Sci 2010;31:403-406.
13. Kobayashi S, Tateno M, Morii H, et al. Decreased cardiac MIBG uptake, its correlation with clinical symptoms in dementia with Lewy bodies. Psychiatry Res 2009;30;174:76-80.
14. Kobayashi K, Sumiya H, Nakano H, et al. Detection of Lewy body disease in patients with late-onset depression, anxiety and psychotic disorder with myocardial meta-iodobenzylguanidine scintigraphy. Int J Geriatr Psychiatry 2010;25:55-65.
15. Mizukami K, Homma T, Aonuma K, et al. Decreased ventilatory response to hypercapnia in dementia with Lewy bodies. Ann Neurol 2009;65:614-617.
16. Escamilla-Sevilla F, Pérez-Navarro MJ, Muñoz-Pasadas M, et al. Diagnostic value of cardiac 123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy in Lewy body disorders. Neurologia 2009;24:170-176.
17. Novellino F, Bagnato A, Salsone M, et al. Myocardial (123)I-MIBG scintigraphy for differentiation of Lewy bodies disease from FTD. Neurobiol Aging 2010;31:1903-1911.
18. Noguchi-Shinohara M, Tokuda T, Yoshita M, et al. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease. Brain Res 2009;1251:1-6.
19. Tateno M, Kobayashi S, Shirasaka T, et al. Comparison of the usefulness of brain perfusion SPECT and MIBG myocardial scintigraphy for the diagnosis of dementia with Lewy bodies. Dement Geriatr Cogn Disord 2008;26:453-457.
20. Kobayashi S, Tateno M, Furukawa Y, et al. Improved diagnosis of dementia with Lewy bodies by the combination of 123I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy and 99mTc-ethylcysteinate dimmer (ECD) brain perfusion SPECT. Seishin Shinkeigaku Zasshi 2008;110:285-291.
21. Miyamoto T, Miyamoto M, Suzuki K, et al. 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 2008;31:717-723.
22. Estorch M, Camacho V, Paredes P, et al. Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging 2008;35:1636-1641.
23. Schmidt SL, Correa PL, Tolentino JC, et al. Value of combining activated brain FDG-PET and cardiac MIBG for the differential diagnosis of dementia: differentiation of dementia with Lewy bodies and Alzheimer disease when the diagnoses based on clinical and neuroimaging criteria are difficult. Clin Nucl Med 2008;33:398-401.
24. Oka H, Yoshioka M, Morita M, et al. Reduced cardiac 123I-MIBG uptake reflects cardiac sympathetic dysfunction in Lewy body disease. Neurology 2007;69:1460-1465.
25. Inui Y, Toyama H, Manabe Y, et al. Evaluation of probable or possible dementia with Lewy bodies using 123I-IMP brain perfusion SPECT, 123I-MIBG, and 99mTc-MIBI myocardial SPECT. J Nucl Med 2007;48:1641-1650.
26. Wada-Isoe K, Imamura K, Kitamaya M, et al. Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J Neurol Sci 2008;266:20-24.
27. Wada-Isoe K, Kitayama M, Nakaso K, et al. Diagnostic markers for diagnosing dementia with Lewy bodies: CSF and MIBG cardiac scintigraphy study. J Neurol Sci 2007;260:33-37.
28. Oka H, Morita M, Onouchi K, et al. Cardiovascular autonomic dysfunction in dementia with Lewy bodies and Parkinson's disease. J Neurol Sci 2007;254:72-77.
29. Hanyu H, Hirao K, Shimizu S, et al. Phenylephrine and pilocarpine eye drop test for dementia with Lewy bodies and Alzheimer's disease. Neurosci Lett 2007;414:174-177.
30. Hanyu H, Shimizu S, Hirao K, et al. The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord 2006;22:379-384.
31. Estorch M, Camacho V, Fuertes J, et al. Dementia with Lewy bodies and Alzheimer's disease: differential diagnosis by cardiac sympathetic innervation MIBG imaging. Rev Esp Med Nucl 2006;25:229-235.
32. Kashihara K, Ohno M, Kawada S, et al. Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure autonomic failure occurs conjointly with Parkinson's disease and dementia with Lewy bodies. J Nucl Med 2006;47:1099-1101.
33. Yoshita M, Taki J, Yokoyama K, et al. Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 2006;66:1850-1854.
34. Hanyu H, Shimizu S, Hirao K, et al. Comparative value of brain perfusion SPECT and [(123)I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer's disease. Eur J Nucl Med Mol Imaging 2006;33:248-253.
35. Suzuki M, Kurita A, Hashimoto M, et al. Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson's disease. J Neurol Sci 2006;240:15-19.
36. Jiménez-Hoyuela García JM, Campos Arillo V, Rebollo Aguirre AC, et al. Early alteration of adrenergic cardiac function in parkinsonisms with Lewy bodies. Rev Esp Med Nucl 2005;24:93-100.
37. Jindahra P, Vejjajiva A, Witoonpanich R, et al. Differentiation of dementia with Lewy bodies, Alzheimer's disease and vascular dementia by cardiac 131I-meta-iodobenzylguanidine (MIBG) uptake (preliminary report). J Med Assoc Thai 2004;87:1176-1181.
38. Saiki S, Hirose G, Sakai K, et al. Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 2004;220:105-111.
39. Oide T, Tokuda T, Momose M, et al. Usefulness of [123I]metaiodobenzylguanidine ([123I]MIBG) myocardial scintigraphy in differentiating between Alzheimer's disease and dementia with Lewy bodies. Intern Med 2003;42:686-690.
40. Yoshita M, Taki J, Yamada M. A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2001;71:583-588.
41. Watanabe H, Ieda T, Katayama T, et al. Cardiac (123)I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001;70:781-783.
42. Nagayama H, Hamamoto M, Ueda M, et al. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson's disease. J Neurol Neurosurg Psychiatry 2005;76:249-251.
43. Verberne HJ, Brewster LM, Somsen GA, et al. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J 2008;29:1147-1159.
44. Sakata K, Iida K, Mochizuki N, et al. Physiological changes in human cardiac sympathetic innervation and activity assessed by 123I-Metaiodobenzylguanidine (MIBG) imaging. Circ J 2009;73:310-315.
45. McKeith I, O'Brien J, Walker Z, et al. DLB Study Group. Sensitivity and specificity of dopamine transporter imaging with 123 I-FP-CIT SPECT in dementia with Lewy bodies: a phase III multicentre study. Lancet Neurol 2007;6:305-313.
46. Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT SPECT imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78:1176-1181.